Quinazoline-based compounds developed after the pharmacological optimization of α1-adrenoceptor antagonists cause phenotypic reversion of EMT to MET and induce anoikis towards overcoming resistance to AR antiandrogens in pre-clinical models of advanced prostate cancer [143,257,258,259]. This evidence concerns the gene AR and prostate cancer.